|
1
|
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial.
|
Lancet
|
2011
|
8.49
|
|
2
|
Routine early angioplasty after fibrinolysis for acute myocardial infarction.
|
N Engl J Med
|
2009
|
6.18
|
|
3
|
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
|
N Engl J Med
|
2010
|
6.05
|
|
4
|
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.
|
JAMA
|
2006
|
5.74
|
|
5
|
Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
|
N Engl J Med
|
2006
|
5.24
|
|
6
|
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.
|
N Engl J Med
|
2010
|
4.73
|
|
7
|
Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials.
|
Am Heart J
|
2008
|
3.38
|
|
8
|
Adverse impact of bleeding on prognosis in patients with acute coronary syndromes.
|
Circulation
|
2006
|
3.22
|
|
9
|
Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation.
|
JAMA
|
2005
|
3.19
|
|
10
|
Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction.
|
JAMA
|
2007
|
3.09
|
|
11
|
Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups.
|
Circulation
|
2002
|
2.89
|
|
12
|
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome.
|
Eur Heart J
|
2011
|
2.40
|
|
13
|
Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
|
Circulation
|
2004
|
2.26
|
|
14
|
Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
|
Circulation
|
2003
|
2.20
|
|
15
|
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study.
|
J Am Coll Cardiol
|
2013
|
2.18
|
|
16
|
Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes.
|
Ann Intern Med
|
2007
|
2.14
|
|
17
|
Early and late effects of clopidogrel in patients with acute coronary syndromes.
|
Circulation
|
2003
|
2.05
|
|
18
|
Differential clinical outcomes associated with hypoglycemia and hyperglycemia in acute myocardial infarction.
|
Circulation
|
2009
|
1.99
|
|
19
|
The risks of waiting for cardiac catheterization: a prospective study.
|
CMAJ
|
2002
|
1.70
|
|
20
|
Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial.
|
JAMA
|
2010
|
1.66
|
|
21
|
Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes.
|
Eur Heart J
|
2008
|
1.65
|
|
22
|
Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials.
|
Circulation
|
2005
|
1.63
|
|
23
|
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
|
Can J Cardiol
|
2013
|
1.54
|
|
24
|
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study.
|
Eur Heart J
|
2008
|
1.52
|
|
25
|
Challenges in the conduct of large simple trials of important generic questions in resource-poor settings: the CREATE and ECLA trial program evaluating GIK (glucose, insulin and potassium) and low-molecular-weight heparin in acute myocardial infarction.
|
Am Heart J
|
2004
|
1.50
|
|
26
|
Design and rationale of the radial versus femoral access for coronary intervention (RIVAL) trial: a randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes.
|
Am Heart J
|
2011
|
1.48
|
|
27
|
Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk.
|
Am Heart J
|
2009
|
1.47
|
|
28
|
Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial.
|
JAMA
|
2013
|
1.45
|
|
29
|
A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions.
|
Am Heart J
|
2006
|
1.41
|
|
30
|
Efficacy and safety of a routine early invasive strategy after fibrinolysis stratified by glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: a pre-specified subgroup analysis of the TRANSFER-AMI randomised controlled trial.
|
Heart
|
2014
|
1.41
|
|
31
|
Sharing Data from Cardiovascular Clinical Trials - A Proposal.
|
N Engl J Med
|
2016
|
1.34
|
|
32
|
Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents.
|
Circulation
|
2010
|
1.20
|
|
33
|
The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis.
|
J Am Coll Cardiol
|
2009
|
1.07
|
|
34
|
Effect of radial versus femoral access on radiation dose and the importance of procedural volume: a substudy of the multicenter randomized RIVAL trial.
|
JACC Cardiovasc Interv
|
2013
|
1.06
|
|
35
|
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.
|
Eur Heart J
|
2012
|
1.02
|
|
36
|
Renal function and outcomes in acute coronary syndrome: impact of clopidogrel.
|
Eur J Cardiovasc Prev Rehabil
|
2007
|
0.98
|
|
37
|
Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment--part 2: ST-segment elevation myocardial infarction.
|
Can J Cardiol
|
2011
|
0.98
|
|
38
|
Aspirin for prevention and treatment of cardiovascular disease.
|
Ann Intern Med
|
2009
|
0.94
|
|
39
|
Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial.
|
Am Heart J
|
2009
|
0.90
|
|
40
|
Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use.
|
Am Heart J
|
2008
|
0.90
|
|
41
|
Incidence, predictors, and clinical significance of troponin-I elevation without creatine kinase elevation following percutaneous coronary interventions.
|
Am J Cardiol
|
2004
|
0.89
|
|
42
|
Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial.
|
Can J Cardiol
|
2007
|
0.89
|
|
43
|
Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction.
|
Am Heart J
|
2009
|
0.85
|
|
44
|
Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes.
|
Eur Heart J
|
2011
|
0.85
|
|
45
|
Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment--part 1: non-ST-segment elevation ACS.
|
Can J Cardiol
|
2011
|
0.83
|
|
46
|
Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events trial and the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events.
|
Circ Cardiovasc Genet
|
2012
|
0.83
|
|
47
|
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.
|
J Am Coll Cardiol
|
2009
|
0.83
|
|
48
|
Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
|
Am Heart J
|
2005
|
0.82
|
|
49
|
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
|
Am Heart J
|
2005
|
0.82
|
|
50
|
Clinical outcomes and cost implications of routine early PCI after fibrinolysis: one-year follow-up of the Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) study.
|
Am Heart J
|
2013
|
0.81
|
|
51
|
Early invasive compared with a selective invasive strategy in women with non-ST-elevation acute coronary syndromes: a substudy of the OASIS 5 trial and a meta-analysis of previous randomized trials.
|
Eur Heart J
|
2009
|
0.81
|
|
52
|
Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute coronary syndrome patients: the Canadian global registry of acute coronary events (GRACE) experience.
|
Am Heart J
|
2009
|
0.80
|
|
53
|
Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery.
|
Ann Thorac Surg
|
2005
|
0.78
|
|
54
|
The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial.
|
Eur Heart J
|
2008
|
0.78
|
|
55
|
Warfarin after bioprosthetic aortic valve implantation.
|
JAMA
|
2012
|
0.77
|
|
56
|
Piloting a novel algorithm for glucose control in the coronary care unit: the RECREATE (REsearching Coronary REduction by Appropriately Targeting Euglycemia) trial.
|
Diabetes Care
|
2011
|
0.77
|
|
57
|
Role of triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents.
|
Med J Aust
|
2010
|
0.76
|
|
58
|
Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) trial.
|
Am Heart J
|
2010
|
0.76
|
|
59
|
Effects of aspiration thrombectomy on mortality in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis of the randomized trials.
|
Indian Heart J
|
2010
|
0.76
|
|
60
|
Aspirin resistance and its implications in clinical practice.
|
MedGenMed
|
2005
|
0.75
|
|
61
|
Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI).
|
Vasc Health Risk Manag
|
2006
|
0.75
|
|
62
|
Aspirin for acute coronary syndromes: have we learned the correct dose yet?
|
Curr Cardiol Rep
|
2010
|
0.75
|
|
63
|
P2Y12 receptor inhibitor resistance and coronary artery disease: a bench to bedside primer for cardiovascular specialists.
|
Curr Opin Cardiol
|
2017
|
0.75
|
|
64
|
Efficacy of early invasive management post-fibrinolysis in men versus women with ST-elevation myocardial infarction: a subgroup analysis from Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI).
|
Am Heart J
|
2012
|
0.75
|
|
65
|
How Should We Treat Multi-Vessel Disease in STEMI Patients?
|
Curr Treat Options Cardiovasc Med
|
2013
|
0.75
|
|
66
|
Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6.
|
Expert Rev Cardiovasc Ther
|
2009
|
0.75
|
|
67
|
Safety and Efficacy of a Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent in Patients with Diabetes: the EVOLVE II Diabetes Substudy.
|
EuroIntervention
|
2016
|
0.75
|
|
68
|
Right ventricular tachycardia: common presentation versus common disease.
|
Circulation
|
2013
|
0.75
|
|
69
|
Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment.
|
Eur Heart J
|
2007
|
0.75
|
|
70
|
Non-infarct related artery revascularization in ST-segment elevation myocardial infarction patients with multivessel disease.
|
Curr Opin Cardiol
|
2017
|
0.75
|
|
71
|
Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy.
|
Am Heart J
|
2012
|
0.75
|
|
72
|
The cost implications of an early versus delayed invasive strategy in Acute Coronary Syndromes: the TIMACS study.
|
J Med Econ
|
2014
|
0.75
|